Device Trial Radar · NCT04210427
Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Dec 12, 2019
Primary completion
Jun 6, 2023
Study completion Jun 6, 2023
Sponsor
- Lead sponsor
- St. Louis UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators will recruit 15 patients with cystic fibrosis 18 years of age and older who present with constipation. The investigators will assess baseline motility symptoms with a survey. Patients will then ingest a SmartPill (trademark) to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
Conditions
- Cystic Fibrosis Gastrointestinal Disease
Interventions
Polyethylene Glycol 3350Drug
All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
SmartPill Motility System & PillCam Patency CapsuleDevice
Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of TherapyTime frame: Change is being assessed: total intestinal transit time (measured in hours) at baseline and two weeks following initiation of therapy with PEG
- Number of Participants With IBS at Baseline and 2 Weeks Post BaselineTime frame: Baseline and 2 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
SSM Health Cardinal Glennon Children's Hosptial
St Louis, Missouri
SSM Health Saint Louis University Hosptial
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.